Skip to main content
Erschienen in: International Journal of Clinical Pharmacy 6/2014

01.12.2014 | Research Article

A study comparing the effectiveness of three warning labels on the package of driving-impairing medicines

verfasst von: Bas Emich, Liset van Dijk, Susana P. Monteiro, Johan J. de Gier

Erschienen in: International Journal of Clinical Pharmacy | Ausgabe 6/2014

Einloggen, um Zugang zu erhalten

Abstract

Background Several medicines are known to potentially impair patients’ driving fitness. Appropriate communication towards patients about this risk can be supported by the use of package warning labels. Objective To compare the effectiveness of a standing practice yellow/black label—with written warning—with a newly developed rating model in communicating risk on driving-impairing medicines (DIMs). Furthermore, the added value of a side-text in the rating model was determined. Setting Community pharmacies in the Netherlands. Method In a cross-sectional study, patients with a first dispensing of a DIM were asked by their community pharmacists (n = 38) to fill out a written questionnaire to compare each of the three warning labels. A 2 [yellow/black label vs. rating model (pair 1) and rating model with side-text vs. rating model without side-text (pair 2)] × 3 [category of driving-impairment: I = minor risk, II = moderate risk, III = severe risk] design was used. The category of driving-impairment varied per respondent, depending on the DIM the patient collected. Main outcome measure: (1) estimated level of driving risk valued by patients (2) intention to change driving behaviour after seeing the warning label. Results An estimated number of 992 patients were approached. As 298 questionnaires were analysed, the net response rate was 30 %. With the yellow/black label, respondents considered DIMs of all three categories of driving-impairment to equally impair driving fitness, while with the rating model the estimated risk was higher when the category referred to a higher level of driving-impairment. Addition of a side-text to the rating model resulted in a significantly higher estimated level of driving risk and a significant increase in intention to change driving behaviour. Only 8.0 % of the patients using a category III DIM estimated the level of driving risk correctly when seeing the yellow/black label, while this was 26.7 % for the rating model and 43.0 % for the rating model with side-text. Conclusion The yellow/black label, which is standing practice in the Netherlands, is less effective in terms of estimated risk and intention to change driving behaviour, compared to a newly developed rating model. This model is even more effective when a side-text is added. Implementation of the rating model in clinical practice should be considered.
Literatur
1.
Zurück zum Zitat Ravera S, Monteiro SP, de Gier JJ, van der Linden T, Gómez-Talegón T, Álvarez FJ, et al. A European approach to categorizing medicines for fitness to drive: outcomes of the DRUID project. Br J Clin Pharmacol. 2012;74(6):920–31.PubMedCentralPubMedCrossRef Ravera S, Monteiro SP, de Gier JJ, van der Linden T, Gómez-Talegón T, Álvarez FJ, et al. A European approach to categorizing medicines for fitness to drive: outcomes of the DRUID project. Br J Clin Pharmacol. 2012;74(6):920–31.PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Corsenac P, Lagarde E, Gadegbeku B, Delorme B, Tricotel A, Castot A, et al. Road traffic crashes and prescribed methadone and buprenorphine: a French registry-based case-control study. Drug Alcohol Depend. 2012;123(1–3):91–7.PubMedCrossRef Corsenac P, Lagarde E, Gadegbeku B, Delorme B, Tricotel A, Castot A, et al. Road traffic crashes and prescribed methadone and buprenorphine: a French registry-based case-control study. Drug Alcohol Depend. 2012;123(1–3):91–7.PubMedCrossRef
3.
Zurück zum Zitat Engeland A, Skurtveit S, Mørland J. Risk of road traffic accidents associated with the prescription of drugs: a registry-based cohort study. Ann Epidemiol. 2007;17(8):597–602.PubMedCrossRef Engeland A, Skurtveit S, Mørland J. Risk of road traffic accidents associated with the prescription of drugs: a registry-based cohort study. Ann Epidemiol. 2007;17(8):597–602.PubMedCrossRef
4.
Zurück zum Zitat Kelly E, Darke S, Ross J. A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions. Drug Alcohol Rev. 2004;23(3):319–44.PubMedCrossRef Kelly E, Darke S, Ross J. A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions. Drug Alcohol Rev. 2004;23(3):319–44.PubMedCrossRef
5.
Zurück zum Zitat Orriols L, Queinec R, Philip P, Gadegbeku B, Delorme B, Moore N, et al. Risk of injurious road traffic crash after prescription of antidepressants. J Clin Psychiatry. 2012;73(8):1088–94.PubMedCrossRef Orriols L, Queinec R, Philip P, Gadegbeku B, Delorme B, Moore N, et al. Risk of injurious road traffic crash after prescription of antidepressants. J Clin Psychiatry. 2012;73(8):1088–94.PubMedCrossRef
6.
Zurück zum Zitat Verster JC, Volkerts ER. Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol. 2004;92(3):294–303.PubMedCrossRef Verster JC, Volkerts ER. Antihistamines and driving ability: evidence from on-the-road driving studies during normal traffic. Ann Allergy Asthma Immunol. 2004;92(3):294–303.PubMedCrossRef
7.
Zurück zum Zitat Verster JC, Veldhuijzen DS, Patat A, Olivier B, Volkerts ER. Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test. Curr Drug Saf. 2006;1(1):63–71.PubMedCrossRef Verster JC, Veldhuijzen DS, Patat A, Olivier B, Volkerts ER. Hypnotics and driving safety: meta-analyses of randomized controlled trials applying the on-the-road driving test. Curr Drug Saf. 2006;1(1):63–71.PubMedCrossRef
10.
Zurück zum Zitat Davis RE, Dolan G, Thomas S, Atwell C, Mead D, Nehammer S, et al. Exploring doctor and patient views about risk communication and shared decision-making in the consultation. Health Expect. 2003;6(3):198–207.PubMedCrossRef Davis RE, Dolan G, Thomas S, Atwell C, Mead D, Nehammer S, et al. Exploring doctor and patient views about risk communication and shared decision-making in the consultation. Health Expect. 2003;6(3):198–207.PubMedCrossRef
11.
Zurück zum Zitat Edwards A, Elwyn G. How should effectiveness of risk communication to aid patients’ decisions be judged?: a review of the literature. Med Decis Making. 1999;19(4):428–34.PubMedCrossRef Edwards A, Elwyn G. How should effectiveness of risk communication to aid patients’ decisions be judged?: a review of the literature. Med Decis Making. 1999;19(4):428–34.PubMedCrossRef
12.
Zurück zum Zitat Edwards A, Elwyn G, Hood K, Robling M, Atwell C, Holmes-Rovner M, et al. The development of COMRADE—a patient-based outcome measure to evaluate the effectiveness of risk communication and treatment decision making in consultations. Patient Educ Couns. 2003;50(3):311–22.PubMedCrossRef Edwards A, Elwyn G, Hood K, Robling M, Atwell C, Holmes-Rovner M, et al. The development of COMRADE—a patient-based outcome measure to evaluate the effectiveness of risk communication and treatment decision making in consultations. Patient Educ Couns. 2003;50(3):311–22.PubMedCrossRef
14.
Zurück zum Zitat Thomson R, Edwards A, Grey J. Risk communication in the clinical consultation. Clin Med. 2005;5(5):465–9.PubMedCrossRef Thomson R, Edwards A, Grey J. Risk communication in the clinical consultation. Clin Med. 2005;5(5):465–9.PubMedCrossRef
15.
Zurück zum Zitat Edwards A, Hood K, Matthews E, Russell D, Russell I, Barker J, et al. The effectiveness of one-to-one risk-communication interventions in health care: a systematic review. Med Decis Making. 2000;20(3):290–7.PubMedCrossRef Edwards A, Hood K, Matthews E, Russell D, Russell I, Barker J, et al. The effectiveness of one-to-one risk-communication interventions in health care: a systematic review. Med Decis Making. 2000;20(3):290–7.PubMedCrossRef
16.
Zurück zum Zitat Wheeler A, Crump K, Lee M, Li L, Patel A, Yang R, Zhao J, Jensen M, et al. Collaborative prescribing: a qualitative exploration of a role for pharmacists in mental health. Res Soc Adm Pharm. 2012;8(38):179–92.CrossRef Wheeler A, Crump K, Lee M, Li L, Patel A, Yang R, Zhao J, Jensen M, et al. Collaborative prescribing: a qualitative exploration of a role for pharmacists in mental health. Res Soc Adm Pharm. 2012;8(38):179–92.CrossRef
17.
Zurück zum Zitat Hill LH, Roslan MR. Using visual concept mapping to communicate medication information to chronic disease patients with low literacy: a preliminary study. Paper presented at first international conference on concept mapping; September 14–17, 2004; Navarra, Spain. Hill LH, Roslan MR. Using visual concept mapping to communicate medication information to chronic disease patients with low literacy: a preliminary study. Paper presented at first international conference on concept mapping; September 14–17, 2004; Navarra, Spain.
18.
Zurück zum Zitat Stout QF, de Gier JJ. Effect van de geel-zwarte rijvaardigheidssticker op geneesmiddelen [Effect of the yellow–black warning label for driving on drugs; article in Dutch]. Pharmaceutisch Weekblad. 1982;117:449–52. Stout QF, de Gier JJ. Effect van de geel-zwarte rijvaardigheidssticker op geneesmiddelen [Effect of the yellow–black warning label for driving on drugs; article in Dutch]. Pharmaceutisch Weekblad. 1982;117:449–52.
19.
Zurück zum Zitat Veldhuijzen DS, van Wijck AJ, Verster JC, Kalkman CJ, Kenemans JL, Olivier B, Volkerts ER. The impact of chronic pain patients’ psychotropic drug knowledge and warning labels on the decision whether to drive a car or not. Traffic Inj Prev. 2006;7(4):360–4.PubMedCrossRef Veldhuijzen DS, van Wijck AJ, Verster JC, Kalkman CJ, Kenemans JL, Olivier B, Volkerts ER. The impact of chronic pain patients’ psychotropic drug knowledge and warning labels on the decision whether to drive a car or not. Traffic Inj Prev. 2006;7(4):360–4.PubMedCrossRef
21.
Zurück zum Zitat Monteiro SP, Huiskes R, van Dijk L, van Weert JCM, de Gier JJ. How effective are pictograms in communicating risk about driving-impairing medicines? Traffic Inj Prev. 2013;14(3):299–308.PubMedCrossRef Monteiro SP, Huiskes R, van Dijk L, van Weert JCM, de Gier JJ. How effective are pictograms in communicating risk about driving-impairing medicines? Traffic Inj Prev. 2013;14(3):299–308.PubMedCrossRef
23.
Zurück zum Zitat Fierro I, Gómez-Talegón T, Álvarez FJ. The Spanish pictogram on medicines and driving: the population’s comprehension of and attitudes towards its use on medication packaging. Accid Anal Prev. 2013;50:1056–61.PubMedCrossRef Fierro I, Gómez-Talegón T, Álvarez FJ. The Spanish pictogram on medicines and driving: the population’s comprehension of and attitudes towards its use on medication packaging. Accid Anal Prev. 2013;50:1056–61.PubMedCrossRef
24.
Zurück zum Zitat Smyth T, Sheehan M, Siskind V, Mercier-Guyon C, Mallaret M. Consumer perceptions of medication warnings about driving: a comparison of French and Australian labels. Traffic Inj Prev. 2013;14(6):557–64.PubMedCrossRef Smyth T, Sheehan M, Siskind V, Mercier-Guyon C, Mallaret M. Consumer perceptions of medication warnings about driving: a comparison of French and Australian labels. Traffic Inj Prev. 2013;14(6):557–64.PubMedCrossRef
25.
Zurück zum Zitat Legrand SA, Boets S, Meesmann U, Verstraete AG. Medicines and driving: evaluation of training and software support for patient counselling by pharmacists. Int J Clin Pharm. 2012;34(4):633–4.PubMedCrossRef Legrand SA, Boets S, Meesmann U, Verstraete AG. Medicines and driving: evaluation of training and software support for patient counselling by pharmacists. Int J Clin Pharm. 2012;34(4):633–4.PubMedCrossRef
26.
Zurück zum Zitat Dowse R, Ehlers M. Medicine labels incorporating pictograms: do they influence understanding and adherence? Patient Educ Couns. 2005;58(1):63–70.PubMedCrossRef Dowse R, Ehlers M. Medicine labels incorporating pictograms: do they influence understanding and adherence? Patient Educ Couns. 2005;58(1):63–70.PubMedCrossRef
27.
Zurück zum Zitat Katz MG, Kripalani S, Weiss BD. Use of pictorial aids in medication instructions: a review of the literature. Am J Health Syst Pharm. 2006;63(23):2391–7.PubMedCrossRef Katz MG, Kripalani S, Weiss BD. Use of pictorial aids in medication instructions: a review of the literature. Am J Health Syst Pharm. 2006;63(23):2391–7.PubMedCrossRef
28.
Zurück zum Zitat Montagne M. Pharmaceutical pictograms: a model for development and testing for comprehension and utility. Res Soc Adm Pharm. 2013;9(5):609–20.CrossRef Montagne M. Pharmaceutical pictograms: a model for development and testing for comprehension and utility. Res Soc Adm Pharm. 2013;9(5):609–20.CrossRef
29.
Zurück zum Zitat Stevens J. Applied multivariate statistics for the social sciences. London: Lawrence Erlbaum Associates; 2002. Stevens J. Applied multivariate statistics for the social sciences. London: Lawrence Erlbaum Associates; 2002.
30.
Zurück zum Zitat SFK (Stichting Farmaceutische Kengetallen). Rijden onder invloed [Driving under influence; article in Dutch]. Pharmaceutisch Weekblad, 2009;144(26):18. SFK (Stichting Farmaceutische Kengetallen). Rijden onder invloed [Driving under influence; article in Dutch]. Pharmaceutisch Weekblad, 2009;144(26):18.
31.
Zurück zum Zitat Wilby K, Marra CA, da Silva JH, Grubisic M, Harvard S, Lynd LD. Randomized controlled trial evaluating pictogram augmentation of HIV medication information. Ann Pharmacother. 2011;45(11):1378–83.PubMedCrossRef Wilby K, Marra CA, da Silva JH, Grubisic M, Harvard S, Lynd LD. Randomized controlled trial evaluating pictogram augmentation of HIV medication information. Ann Pharmacother. 2011;45(11):1378–83.PubMedCrossRef
Metadaten
Titel
A study comparing the effectiveness of three warning labels on the package of driving-impairing medicines
verfasst von
Bas Emich
Liset van Dijk
Susana P. Monteiro
Johan J. de Gier
Publikationsdatum
01.12.2014
Verlag
Springer Netherlands
Erschienen in
International Journal of Clinical Pharmacy / Ausgabe 6/2014
Print ISSN: 2210-7703
Elektronische ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-014-0010-2

Weitere Artikel der Ausgabe 6/2014

International Journal of Clinical Pharmacy 6/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Reizdarmsyndrom: Diäten wirksamer als Medikamente

29.04.2024 Reizdarmsyndrom Nachrichten

Bei Reizdarmsyndrom scheinen Diäten, wie etwa die FODMAP-arme oder die kohlenhydratreduzierte Ernährung, effektiver als eine medikamentöse Therapie zu sein. Das hat eine Studie aus Schweden ergeben, die die drei Therapieoptionen im direkten Vergleich analysierte.

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.